TargetBeta
TUBB1
tubulin beta 1 class VI · also dJ543J19.4 · Tubulin beta family
6 programs in company-led studies act on TUBB1, from 5 companies: 2 in phase 3, 4 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (6 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| Docetaxelrule | Sanofi | phase 4 | 19932 running | TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3E, TUBA4A, TUBB, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 | ChEMBL |
| Paclitaxelrule | Hoffmann-La Roche | phase 4 | 20230 running | TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3E, TUBA4A, TUBB, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 | ChEMBL |
| Vinblastinerule | Takeda | phase 4 | 42 running | TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3E, TUBA4A, TUBB, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 | ChEMBL |
| cabazitaxelrule | Sanofi | phase 4 | 211 running | TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3E, TUBA4A, TUBB, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 | ChEMBL |
| desoxyepothilone Brule | Beijing Biostar Pharmaceuticals | phase 3 | 199 running | TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3E, TUBA4A, TUBB, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 | ChEMBL |
| plinabulinrule | BeyondSpring Pharmaceuticals | phase 3 | 82 running | TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3E, TUBA4A, TUBB, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 | ChEMBL |
Also acted on by the same programs
Conditions their studies are in
- Carcinoma, Non-Small-Cell Lung, 4 programs
- Breast Neoplasms, 3 programs
- Neoplasms, 3 programs
- Stomach Neoplasms, 3 programs
- Lung Neoplasms, 2 programs
- Ovarian Neoplasms, 2 programs
- Prostatic Neoplasms, 2 programs
- Brain Neoplasms, 1 program
- Carcinoma, Renal Cell, 1 program
- Hodgkin Disease, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Nov 2026Docetaxel · Sanofi · phase 4 · NCT06118333
- Nov 18, 2026Paclitaxel · Hoffmann-La Roche · phase 4 · NCT06693336
- Dec 2026cabazitaxel · Sanofi · phase 4 · NCT06890832
- Dec 1, 2026desoxyepothilone B · Beijing Biostar Pharmaceuticals · phase 3 · NCT06683703
- Mar 31, 2028Vinblastine · Takeda · phase 4 · NCT06831370
- Jun 1, 2029plinabulin · BeyondSpring Pharmaceuticals · phase 3 · NCT07361484
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.